03.14.2019 | Germany joins CARB-X partnership in the fight against deadly drug-resistant superbugs
CARB-X announced today it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early development of antibiotics, vaccines, and diagnostics to combat drug-resistant bacteria. Under the agreement, BMBF will also provide an additional €1 million in direct support to a consortium of the German Center for Infection Research (DZIF), the Federal Institute for Vaccines and Biomedicines (PEI) and the Federal Institute for Drugs and Medical Devices (BfArM), which is joining the CARB-X Global Accelerator Network, a network of 10 accelerators around the world to support CARB-X funded projects. CARB-X is a global non-profit partnership housed at Boston University.
03.04.2019 | CARB-X funds ContraFect to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs
CARB-X is awarding ContraFect Corporation (Nasdaq:CFRX) of Yonkers, New York, USA, up to $1.75 million in non-dilutive funding with the possibility of $5.19 million more if certain project milestones are met, to develop novel antibiotics to treat serious life-threatening infections caused by Gram-negative ESKAPE pathogens. This is ContraFect’s second antibacterial project to earn CARB-X funding.
02.25.2019 | CARB-X expands its Global Accelerator Network to support the development of antibiotics, rapid diagnostics, vaccines and other life-saving products to combat drug-resistant superbugs
CARB-X is expanding its Global Accelerator Network, bringing together 10 world-class organizations from six countries (Denmark, Germany, India, Switzerland, United Kingdom, United States) into a single global network of expertise to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects. The new accelerators join CARB-X’s existing accelerator partners – CLSI, MassBio and RTI International in the United States and the Wellcome Trust in the United Kingdom.
02.06.2019 | CARB-X funds Recida Therapeutics to develop a new class of antibiotics to treat deadly infections caused by Gram-negative superbugs
CARB-X is awarding Recida Therapeutics of Menlo Park, CA, USA, up to $4.4 million in non-dilutive funding to develop a novel antibiotic to treat serious infections caused by Gram-negative bacteria.
02.04.2019 | CARB-X funds Polyphor to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs
CARB-X is awarding Polyphor (SIX: POLN) of Allschwil, Switzerland, up to $2.6 million in non-dilutive funding with the possibility of $3.0 million more if certain project milestones are met, to develop a novel antibiotic with a novel mode of action to treat serious infections caused by Gram-negative ESKAPE pathogens.
01.03.2019 | CARB-X backs Forge to develop a new class of antibiotics to treat serious lung infections caused by Gram-negative bacteria, including multi-drug resistant P. aeruginosa
CARB-X is awarding Forge Therapeutics of San Diego, CA, USA, up to $5.7 million in non-dilutive funding, with the possibility of up to $5.4 million more if certain project milestones are met, to develop a novel antibiotic to treat serious lung infections caused by Gram-negative bacteria including multi-drug resistant Pseudomonas aeruginosa. This is Forge’s second project to earn CARB-X support